The role of hypoxia-inducible factor-1α and -2α in androgen insensitive prostate cancer cells

Urologic Oncology: Seminars and Original Investigations

Volumn 31, Issue 8, 2013, Pages 1448-1456

  Jeong, Chang Wook ^a   Yoon, Cheol Yong ^a   Jeong, Seong Jin ^a   Hong, Sung Kyu ^a   Byun, Seok Soo ^a   Kwak, Cheol ^b   Lee, Sang Eun ^a  

^a Seoul National University Bundang Hospital   (South Korea)

^b Seoul National University Hospital   (South Korea)

Author keywords

Hypoxia inducible factor; Prostate cancer; SiRNA; Zinc

Indexed keywords

DOCETAXEL; GLUCOSE TRANSPORTER 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 2ALPHA; MATRIGEL; PROTEIN P21; SMALL INTERFERING RNA; SOMATOMEDIN C; SORAFENIB; SUNITINIB; ZINC SULFATE;

ARTICLE; CANCER CELL; CANCER RESISTANCE; CELL COUNT; CELL INVASION; CELL PROLIFERATION; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; GENE EXPRESSION; GENE INDUCTION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MALE; MOLECULAR MECHANICS; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; WESTERN BLOTTING;

HYPOXIA-INDUCIBLE FACTOR; PROSTATE CANCER; SIRNA; ZINC;

ANTINEOPLASTIC AGENTS; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL MOVEMENT; CELL SURVIVAL; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION REGULATION, NEOPLASTIC; GLUCOSE TRANSPORTER TYPE 1; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; INDOLES; INSULIN-LIKE GROWTH FACTOR I; MALE; NIACINAMIDE; PHENYLUREA COMPOUNDS; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; PROTO-ONCOGENE PROTEINS C-MET; PYRROLES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; TAXOIDS; ZINC SULFATE;

EID: 84886253579     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2012.03.022     Document Type: Article

References (26)

1. Jemal A., Bray F., Center M.M., et al. Global cancer statistics. CA Cancer J Clin 2011, 61:69-90.
2. Goktas S., Crawford E.D. Optimal hormonal therapy for advanced prostatic carcinoma. Semin Oncol 1999, 26:162-173.
3. Feldman B.J., Feldman D. The development of androgen-independent prostate cancer. Nat Rev Cancer 2001, 1:34-45.
4. Di Lorenzo G., Autorino R., Figg W.D., et al. Hormone-refractory prostate cancer: Where are we going?. Drugs 2007, 67:1109-1124.
5. Kimbro K.S., Simons J.W. Hypoxia-inducible factor-1 in human breast and prostate cancer. Endocr Relat Cancer 2006, 13:739-749.
6. Semenza G.L. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003, 3:721-732.
7. Zhong H., De Marzo A.M., Laughner E., et al. Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res 1999, 59:5830-5835.
8. Zhong H., Semenza G.L., Simons J.W., et al. Up-regulation of hypoxia-inducible factor 1alpha is an early event in prostate carcinogenesis. Cancer Detect Prev 2004, 28:88-93.
9. Vergis R., Corbishley C.M., Norman A.R., et al. Intrinsic markers of tumor hypoxia and angiogenesis in localized prostate cancer and outcome of radical treatment: A retrospective analysis of two randomized radiotherapy trials and one surgical cohort study. Lancet Oncol 2008, 9:342-351.
10. Park S.E., Park J.W., Cho Y.S., et al. HIF-1&;α promotes survival of prostate cells at a high zinc environment. Prostate 2007, 67:1514-1523.
11. Costello L.C., Franklin R.B., Feng P., et al. Zinc and prostate cancer: A critical scientific, medical, and public interest issue (United States). Cancer Causes Control 2005, 16:901-915.
12. Löfstedt T., Fredlund E., Holmquist-Mengelbier L., et al. Hypoxia inducible factor-2alpha in cancer. Cell Cycle 2007, 6:919-926.
13. Loboda A., Jozkowicz A., Dulak J. HIF-1 and HIF-2 transcription factors-Similar but not identical. Mol Cells 2010, 29:435-442.
14. Blancher C., Moore J.W., Talks K.L., et al. Relationship of hypoxia-inducible factor (HIF)-1&;α and HIF-2&;α expression to vascular endothelial growth factor induction and hypoxia survival in human breast cancer cell lines. Cancer Res 2000, 60:7106-7113.
15. Raval R.R., Lau K.W., Tran M.G., et al. Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma. Mol Cell Biol 2005, 25:5675-5686.
16. Makino Y., Uenishi R., Okamoto K., et al. Transcriptional up-regulation of inhibitory PAS domain protein gene expression by hypoxia-inducible factor 1 (HIF-1): A negative feedback regulatory circuit in HIF-1-mediated signaling in hypoxic cells. J Biol Chem 2007, 282:14073-14082.
17. Ku J.H., Seo S.Y., Kwak C., et al. The role of survivin and Bcl-2 in zinc-induced apoptosis in prostate cancer cells. Urol Oncol 2010 Sep 3, [Epub ahead of print].
18. Liu X., Fu Y.M., Meadows G.G. Differential effects of specific amino acid restriction on glucose metabolism, reduction/oxidation status and mitochondrial damage in DU145 and PC3 prostate cancer cells. Oncol Lett 2011, 2:349-355.
19. Petrylak D.P., Tangen C.M., Hussain M.H., et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004, 351:1513-1520.
20. Tannock I.F., de Wit R., Berry W.R., et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004, 351:1502-1512.
21. Rohwer N., Cramer T. Hypoxia-mediated drug resistance: Novel insights on the functional interaction of HIFs and cell death pathways. Drug Resist Update 2011, 14:191-201.
22. Merino M., Pinto A., González R., et al. Antiangiogenic agents and endothelin antagonists in advanced castration resistant prostate cancer. Eur J Cancer 2011, 47:1846-1851.
23. Nilsson M.B., Zage P.E., Zeng L., et al. Multiple receptor tyrosine kinases regulate HIF-1alpha and HIF-2alpha in normoxia and hypoxia in neuroblastoma: Implications for anti-angiogenic mechanisms of multikinase inhibitors. Oncogene 2010, 29:2938-2949.
24. Beardsley E.K., Hotte S.J., North S., et al. A phase II study of sorafenib in combination with bicalutamide in patients with chemotherapy-naive castration resistant prostate cancer. Invest New Drugs 2011 Jul 23, [Epub ahead of print].
25. Zurita A.J., George D.J., Shore N.D., et al. Sunitinib in combination with docetaxel and prednisone in chemotherapy-naive patients with metastatic, castration-resistant prostate cancer: A phase 1/2 clinical trial. Ann Oncol 2012, 23:688-694.
26. Nordgren I.K., Tavassoli A. Targeting tumour angiogenesis with small molecule inhibitors of hypoxia inducible factor. Chem Soc Rev 2011, 40:4307-4317.